GlassScriptPhysician profile
Courtney Mitchell
NPI 1720659204
$8,577.19
in general payments reported to CMS, 2019-2025
42 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $857 · 2022: $1,681 · 2023: $2,343 · 2024: $1,870 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,039.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,161.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,064.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $778.74 | 2022-2025 | |
| Glaxosmithkline, LLC. | $702.25 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $574.34 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $477.77 | 2021-2025 | |
| Lilly USA, LLC | $429.26 | 2021-2025 | Emgality, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $391.90 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.93 | 2021-2024 | Jardiance |
| Amgen INC. | $259.86 | 2021-2025 | Repatha, Otezla, Otezla |
| Axsome Therapeutics, INC. | $183.99 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $150.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $149.49 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Jazz Pharmaceuticals INC. | $145.47 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.27 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $139.11 | 2021-2023 | |
| Exact Sciences Corporation | $136.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $135.43 | 2022-2024 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $125.33 | 2021 | |
| Merck Sharp & Dohme LLC | $110.91 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Lundbeck LLC | $108.85 | 2022-2024 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.94 | 2021-2023 | Xifaxan, Cycloset |
| Dexcom, INC. | $94.28 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $79.80 | 2024-2025 | Voquezna |
| Verona Pharma, INC. | $76.16 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $70.02 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $68.67 | 2023-2024 | Edarbi, Edarbi |
| Astellas Pharma US INC | $66.92 | 2021-2025 | Veozah |
| Abbott Laboratories | $64.81 | 2023-2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $62.13 | 2022-2023 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $47.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $39.61 | 2022-2023 | Quviviq |
| Antares Pharma, INC. | $28.94 | 2023 | Xyosted, Tlando, Nocdurna |
| Amneal Pharmaceuticals LLC | $18.38 | 2021 | |
| Amarin Pharma, INC. | $18.02 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.54 | 2025 | Keveyis |
| Medtronic, INC. | $17.49 | 2025 | Venaseal |
| Nestle Healthcare Nutrition INC. | $16.27 | 2023 | |
| Esperion Therapeutics, INC. | $14.73 | 2025 | Nexletol |
| Almatica Pharma LLC | $14.58 | 2024 | Teriparatide, Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $12.68 | 2022 | |
| Exeltis, USA INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.